<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316341</url>
  </required_header>
  <id_info>
    <org_study_id>1245.44</org_study_id>
    <nct_id>NCT01316341</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of BI 10773 After Single and Multiple Oral Dose of 10 mg and 25 mg BI 10773 in Chinese Male and Female Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      the pharmacokinetics, pharmacodynamics and safety and tolerability of single and multiple
      oral doses of BI 10773 at low dose once daily (q.d.) and high dose q.d. administered to
      Chinese female and male patients with type 2 diabetes will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Measured Concentration (Cmax)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Maximum measured concentration of the analyte in plasma after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Measured Concentration (Tmax)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Time from dosing to the maximum measured concentration of the analyte in plasma, after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve 0 to Infinity (AUC0-∞) After Single Dosing</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity, after the first dose on day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point, after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Rate Constant (λz)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Terminal Rate Constant in Plasma (λz), after the first dose on day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Terminal half-life of empagliflozin (empa) in plasma after the first dose on day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time (MRTpo)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Mean residence time of empagliflozin (empa) in the body after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance of Empagliflozin After Extravascular Administration (CL/F)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Apparent clearance of empagliflozin (empa) in plasma after extravascular administration, after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase λz (Vz/F)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Apparent volume of distribution during the terminal phase λz, after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Empagliflozin Eliminated in Urine in the Time Interval 0 Hours to 24 Hours (Ae 0-24)</measure>
    <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
    <description>Amount of empagliflozin (empa) eliminated in urine in the time interval 0 hours to 24 hours, after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of Empagliflozin Excreted Unchanged in Urine in the Time Interval 0 Hours to 24 Hours (fe 0-24).</measure>
    <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
    <description>Fraction of empagliflozin (empa) excreted unchanged in urine in the time interval 0 hours to 24 hours, after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance After Extravascular Administration (CL R,0-48)</measure>
    <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
    <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration, after the first dose on day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Measured Concentration Over a Uniform Dosing Interval (Cmax,ss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Maximum measured concentration of empagliflozin (empa) in plasma at steady state over a uniform dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time From Last Dosing to Maximum Measured Concentration Over a Uniform Dosing Interval at Steady State (Tmax,ss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Time from last dosing to maximum measured concentration of empagliflozin (empa) in plasma over a uniform dosing interval at steady state, after multiple dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve in Plasma at Steady State Over a Uniform Dosing Interval (AUCτ,ss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Area under the concentration-time curve of empagliflozin (empa) in plasma at steady state over a uniform dosing interval, after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Rate Constant in Plasma at Steady State (λz,ss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Terminal rate constant in plasma at steady state, after multiple dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life in Plasma at Steady State (t1/2,ss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Terminal half-life of empagliflozin (empa) in plasma at steady state, after multiple dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time at Steady State (MRTpo,ss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Mean residence time of empagliflozin (empa) in the body at steady state after multiple oral administrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance of Empagliflozin After Extravascular Administration (CL/Fss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Apparent clearance of empagliflozin (empa) in the plasma at steady state following multiple oral dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase λz (Vz/Fss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Apparent volume of distribution during the terminal phase λz at steady state following oral administration after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Analyte Eliminated in Urine at Steady State in Time Interval 0 Hours to 24 Hours (Ae 0-24,ss)</measure>
    <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
    <description>Amount of empagliflozin (empa) eliminated in urine at steady state in the time interval 0 hours to 24 hours, after multiple dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of Empagliflozin Excreted Unchanged in Urine at Steady State in the Time Interval 0 Hours to 24 Hours (fe 0-24,ss)</measure>
    <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
    <description>Fraction of empagliflozin (empa) excreted unchanged in urine at steady state in the time interval 0 hours to 24 hours, after multiple dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance at Steady State (CL R,ss)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
    <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration, after multiple dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio Based on AUC (R A,AUC)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, and16h after drug administration on days 1 and 9</time_frame>
    <description>Accumulation ratio of empagliflozin (empa) based on AUC, after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio Based on Cmax (R A,Cmax)</measure>
    <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, and16h after drug administration between days 5 and 9</time_frame>
    <description>Accumulation ratio of empagliflozin (empa) based on Cmax, after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predose Plasma Concentration Before Planned Dose x (Cpre,x)</measure>
    <time_frame>5 minutes before drug administration</time_frame>
    <description>Predose plasma concentration of empagliflozin (empa) before planned dose by day.
This endpoint in steady state is identical to Cmin,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Glucose Excretion (UGE) Change From Baseline</measure>
    <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
    <description>Change from day -1 in urinary glucose excretion in a 24 hour collection period per time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline</measure>
    <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
    <description>Fasting Plasma Glucose (FPG) change from baseline between day 1 and day 9.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Protocol-Specified Significant Adverse Events, Hypoglycaemic Events, Vital Signs, Blood Chemistry, Rescue Therapy, Body Weight and Waist Circumference</measure>
    <time_frame>Drug administration until end of trial, up to 21 days</time_frame>
    <description>Clinically relevant abnormalities for protocol-specified significant adverse events, hypoglycaemic events, vital signs, blood chemistry, use of rescue therapy, change in body weight and change in waist circumference.
Results shown are for hypoglycaemic events, as this was the only event that occurred for this endpoint.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI10773 low dose Per Os(p.o.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing low dose BI10773 Per Os(p.o.) plus one placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient to receive two placebos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI10773 high dose Per Os(p.o.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing high dose BI10773 Per Os(p.o.) plus one placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI10773</intervention_name>
    <description>patient to receive a tablet containing high dose BI10773 p.o. plus one placebo</description>
    <arm_group_label>BI10773 high dose Per Os(p.o.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patient to receive two placebos</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patient to receive two placebos</description>
    <arm_group_label>BI10773 low dose Per Os(p.o.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patient to receive two placebos</description>
    <arm_group_label>BI10773 high dose Per Os(p.o.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI10773</intervention_name>
    <description>patient to receive a tablet containing low dose BI10773 p.o. plus one placebo</description>
    <arm_group_label>BI10773 low dose Per Os(p.o.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Chinese male and female patients with proven diagnosis of type 2 diabetes mellitus
             treated with diet and exercise only or on a maximum of two oral antidiabetic agents
             except thiazolidinediones with at least one agent taken at 50% of its maximum dose or
             less, unchanged for at least 12 weeks before randomization

          2. Glycosylated haemoglobin A1(HbA1c)&lt;=8.5% and &gt;=7.0% at screening,age&gt;=21 and age&lt;=70
             years (male and female patients),BMI&gt;=19 and &lt;=40 kg/m2

          3. Signed and dated written informed consent by date of Visit 1 in accordance with GCP
             and local legislation.

        Exclusion criteria:

          1. Patient who did not discontinue the antidiabetic treatment with insulin or glitazones,
             DPP-IV at least before 12 weeks before randomization

          2. Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an
             overnight fast at screening visit

          3. Clinically relevant concomitant diseases other than type 2 diabetes, hyperlipidaemia
             and medically treated hypertension, such as:

        4 Any late stage complication of diabetes (e.g. retinopathy, polyneuropathy, vegetative
        disorders, diabetic foot) 5 Renal insufficiency (calculated creatinine clearance &lt; 80
        ml/min/1.73m²) 6 Cardiac insufficiency NYHA II-IV, myocardial infarction, other known
        cardiovascular diseases including hypertension &gt; 160/95mmHg (measured at training visit and
        each of the timepoints of Day -1), stroke and TIA 7 Neurological disorders (such as
        epilepsy) or psychiatric disorders 8 Acute or relevant chronic infections (e.g. HIV,
        repeated urogenital infections) 9 Any gastrointestinal, hepatic, respiratory, endocrine or
        immunological disorder 10. History of relevant allergy/hypersensitivity (including allergy
        to drug or its excipients) 11. A marked baseline prolongation of QT/QTc interval (e.g., ECG
        demonstration of a QTc interval &gt;450 ms ) at screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.44.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Two placebo tablets, one matching the empa 10mg tablet and one matching the empa 25mg tablet, taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period).</description>
        </group>
        <group group_id="P2">
          <title>Empa 10 mg</title>
          <description>10 mg Empagliflozin (empa) taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period). Along with this a placebo tablet matching the 25mg empa tablet was taken at each drug administration.</description>
        </group>
        <group group_id="P3">
          <title>Empa 25 mg</title>
          <description>25 mg Empagliflozin (empa) taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period). Along with this a placebo tablet matching the 10mg empa tablet was taken at each drug administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Two placebo tablets, one matching the empa 10mg tablet and one matching the empa 25mg tablet, taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period).</description>
        </group>
        <group group_id="B2">
          <title>Empa 10 mg</title>
          <description>10 mg Empagliflozin (empa) taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period). Along with this a placebo tablet matching the 25mg empa tablet was taken at each drug administration.</description>
        </group>
        <group group_id="B3">
          <title>Empa 25 mg</title>
          <description>25 mg Empagliflozin (empa) taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period). Along with this a placebo tablet matching the 10mg empa tablet was taken at each drug administration.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="9.6"/>
                    <measurement group_id="B2" value="54.1" spread="7.9"/>
                    <measurement group_id="B3" value="52.7" spread="9.9"/>
                    <measurement group_id="B4" value="53.4" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of the analyte in plasma after the first dose on day 1.</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of the analyte in plasma after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" spread="14.1"/>
                    <measurement group_id="O2" value="1090" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Measured Concentration (Tmax)</title>
        <description>Time from dosing to the maximum measured concentration of the analyte in plasma, after the first dose on day 1.</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Measured Concentration (Tmax)</title>
          <description>Time from dosing to the maximum measured concentration of the analyte in plasma, after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="33.3"/>
                    <measurement group_id="O2" value="1.50" spread="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve 0 to Infinity (AUC0-∞) After Single Dosing</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity, after the first dose on day 1</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0 to Infinity (AUC0-∞) After Single Dosing</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 extrapolated to infinity, after the first dose on day 1</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2560" spread="12.3"/>
                    <measurement group_id="O2" value="7250" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point, after the first dose on day 1.</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma over the time interval from 0 to the time of the last quantifiable data point, after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2510" spread="12.3"/>
                    <measurement group_id="O2" value="7070" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Rate Constant (λz)</title>
        <description>Terminal Rate Constant in Plasma (λz), after the first dose on day 1</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant (λz)</title>
          <description>Terminal Rate Constant in Plasma (λz), after the first dose on day 1</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0749" spread="30.3"/>
                    <measurement group_id="O2" value="0.0664" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (t1/2)</title>
        <description>Terminal half-life of empagliflozin (empa) in plasma after the first dose on day 1</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2)</title>
          <description>Terminal half-life of empagliflozin (empa) in plasma after the first dose on day 1</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.25" spread="30.3"/>
                    <measurement group_id="O2" value="10.4" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Residence Time (MRTpo)</title>
        <description>Mean residence time of empagliflozin (empa) in the body after the first dose on day 1.</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRTpo)</title>
          <description>Mean residence time of empagliflozin (empa) in the body after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.29" spread="16.4"/>
                    <measurement group_id="O2" value="10.2" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance of Empagliflozin After Extravascular Administration (CL/F)</title>
        <description>Apparent clearance of empagliflozin (empa) in plasma after extravascular administration, after the first dose on day 1.</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of Empagliflozin After Extravascular Administration (CL/F)</title>
          <description>Apparent clearance of empagliflozin (empa) in plasma after extravascular administration, after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="12.3"/>
                    <measurement group_id="O2" value="127" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase λz (Vz/F)</title>
        <description>Apparent volume of distribution during the terminal phase λz, after the first dose on day 1.</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase λz (Vz/F)</title>
          <description>Apparent volume of distribution during the terminal phase λz, after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="31.8"/>
                    <measurement group_id="O2" value="115" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Empagliflozin Eliminated in Urine in the Time Interval 0 Hours to 24 Hours (Ae 0-24)</title>
        <description>Amount of empagliflozin (empa) eliminated in urine in the time interval 0 hours to 24 hours, after the first dose on day 1.</description>
        <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Empagliflozin Eliminated in Urine in the Time Interval 0 Hours to 24 Hours (Ae 0-24)</title>
          <description>Amount of empagliflozin (empa) eliminated in urine in the time interval 0 hours to 24 hours, after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4030" spread="18.9"/>
                    <measurement group_id="O2" value="9940" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fraction of Empagliflozin Excreted Unchanged in Urine in the Time Interval 0 Hours to 24 Hours (fe 0-24).</title>
        <description>Fraction of empagliflozin (empa) excreted unchanged in urine in the time interval 0 hours to 24 hours, after the first dose on day 1.</description>
        <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Empagliflozin Excreted Unchanged in Urine in the Time Interval 0 Hours to 24 Hours (fe 0-24).</title>
          <description>Fraction of empagliflozin (empa) excreted unchanged in urine in the time interval 0 hours to 24 hours, after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>percentage of empa</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="18.9"/>
                    <measurement group_id="O2" value="17.9" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance After Extravascular Administration (CL R,0-48)</title>
        <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration, after the first dose on day 1.</description>
        <time_frame>5 minutes (min) before drug administration and 10 min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 25mg empa tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally as a single dose, plus a placebo tablet matching the 10mg empa tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance After Extravascular Administration (CL R,0-48)</title>
          <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration, after the first dose on day 1.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="22.6"/>
                    <measurement group_id="O2" value="25.6" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration Over a Uniform Dosing Interval (Cmax,ss)</title>
        <description>Maximum measured concentration of empagliflozin (empa) in plasma at steady state over a uniform dosing interval.</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration Over a Uniform Dosing Interval (Cmax,ss)</title>
          <description>Maximum measured concentration of empagliflozin (empa) in plasma at steady state over a uniform dosing interval.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489" spread="27.4"/>
                    <measurement group_id="O2" value="1250" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time From Last Dosing to Maximum Measured Concentration Over a Uniform Dosing Interval at Steady State (Tmax,ss)</title>
        <description>Time from last dosing to maximum measured concentration of empagliflozin (empa) in plasma over a uniform dosing interval at steady state, after multiple dosing.</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Last Dosing to Maximum Measured Concentration Over a Uniform Dosing Interval at Steady State (Tmax,ss)</title>
          <description>Time from last dosing to maximum measured concentration of empagliflozin (empa) in plasma over a uniform dosing interval at steady state, after multiple dosing.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="43.8"/>
                    <measurement group_id="O2" value="1.37" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve in Plasma at Steady State Over a Uniform Dosing Interval (AUCτ,ss)</title>
        <description>Area under the concentration-time curve of empagliflozin (empa) in plasma at steady state over a uniform dosing interval, after multiple dosing</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve in Plasma at Steady State Over a Uniform Dosing Interval (AUCτ,ss)</title>
          <description>Area under the concentration-time curve of empagliflozin (empa) in plasma at steady state over a uniform dosing interval, after multiple dosing</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2650" spread="15.4"/>
                    <measurement group_id="O2" value="7520" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Rate Constant in Plasma at Steady State (λz,ss)</title>
        <description>Terminal rate constant in plasma at steady state, after multiple dosing.</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant in Plasma at Steady State (λz,ss)</title>
          <description>Terminal rate constant in plasma at steady state, after multiple dosing.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0559" spread="52.5"/>
                    <measurement group_id="O2" value="0.0588" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life in Plasma at Steady State (t1/2,ss)</title>
        <description>Terminal half-life of empagliflozin (empa) in plasma at steady state, after multiple dosing.</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life in Plasma at Steady State (t1/2,ss)</title>
          <description>Terminal half-life of empagliflozin (empa) in plasma at steady state, after multiple dosing.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="52.5"/>
                    <measurement group_id="O2" value="11.8" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Residence Time at Steady State (MRTpo,ss)</title>
        <description>Mean residence time of empagliflozin (empa) in the body at steady state after multiple oral administrations</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time at Steady State (MRTpo,ss)</title>
          <description>Mean residence time of empagliflozin (empa) in the body at steady state after multiple oral administrations</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="18.5"/>
                    <measurement group_id="O2" value="10.2" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Clearance of Empagliflozin After Extravascular Administration (CL/Fss)</title>
        <description>Apparent clearance of empagliflozin (empa) in the plasma at steady state following multiple oral dose administration.</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance of Empagliflozin After Extravascular Administration (CL/Fss)</title>
          <description>Apparent clearance of empagliflozin (empa) in the plasma at steady state following multiple oral dose administration.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" spread="15.4"/>
                    <measurement group_id="O2" value="123" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase λz (Vz/Fss)</title>
        <description>Apparent volume of distribution during the terminal phase λz at steady state following oral administration after multiple dosing</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase λz (Vz/Fss)</title>
          <description>Apparent volume of distribution during the terminal phase λz at steady state following oral administration after multiple dosing</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" spread="55.1"/>
                    <measurement group_id="O2" value="125" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Analyte Eliminated in Urine at Steady State in Time Interval 0 Hours to 24 Hours (Ae 0-24,ss)</title>
        <description>Amount of empagliflozin (empa) eliminated in urine at steady state in the time interval 0 hours to 24 hours, after multiple dosing.</description>
        <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Analyte Eliminated in Urine at Steady State in Time Interval 0 Hours to 24 Hours (Ae 0-24,ss)</title>
          <description>Amount of empagliflozin (empa) eliminated in urine at steady state in the time interval 0 hours to 24 hours, after multiple dosing.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4420" spread="14.6"/>
                    <measurement group_id="O2" value="11600" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fraction of Empagliflozin Excreted Unchanged in Urine at Steady State in the Time Interval 0 Hours to 24 Hours (fe 0-24,ss)</title>
        <description>Fraction of empagliflozin (empa) excreted unchanged in urine at steady state in the time interval 0 hours to 24 hours, after multiple dosing.</description>
        <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Empagliflozin Excreted Unchanged in Urine at Steady State in the Time Interval 0 Hours to 24 Hours (fe 0-24,ss)</title>
          <description>Fraction of empagliflozin (empa) excreted unchanged in urine at steady state in the time interval 0 hours to 24 hours, after multiple dosing.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>percentage of empa</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="14.6"/>
                    <measurement group_id="O2" value="20.9" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance at Steady State (CL R,ss)</title>
        <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration, after multiple dosing.</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 36h 48h, 60h, 72h and 96h after drug administration on day 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance at Steady State (CL R,ss)</title>
          <description>Renal clearance of empagliflozin (empa) in plasma after extravascular administration, after multiple dosing.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="15.8"/>
                    <measurement group_id="O2" value="26.1" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio Based on AUC (R A,AUC)</title>
        <description>Accumulation ratio of empagliflozin (empa) based on AUC, after multiple dosing</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, and16h after drug administration on days 1 and 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio Based on AUC (R A,AUC)</title>
          <description>Accumulation ratio of empagliflozin (empa) based on AUC, after multiple dosing</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="12.0"/>
                    <measurement group_id="O2" value="1.17" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio Based on Cmax (R A,Cmax)</title>
        <description>Accumulation ratio of empagliflozin (empa) based on Cmax, after multiple dosing</description>
        <time_frame>5 minutes (min) before drug administration and 10min, 20min, 30min, 40min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, and16h after drug administration between days 5 and 9</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio Based on Cmax (R A,Cmax)</title>
          <description>Accumulation ratio of empagliflozin (empa) based on Cmax, after multiple dosing</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="32.0"/>
                    <measurement group_id="O2" value="1.15" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Predose Plasma Concentration Before Planned Dose x (Cpre,x)</title>
        <description>Predose plasma concentration of empagliflozin (empa) before planned dose by day.
This endpoint in steady state is identical to Cmin,ss.</description>
        <time_frame>5 minutes before drug administration</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 10 mg</title>
            <description>A single dose of 10 mg Empagliflozin (empa) taken orally, plus one placebo tablet.</description>
          </group>
          <group group_id="O2">
            <title>Empa 25 mg</title>
            <description>A single dose of 25 mg empagliflozin (empa) taken orally, plus one placebo tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Predose Plasma Concentration Before Planned Dose x (Cpre,x)</title>
          <description>Predose plasma concentration of empagliflozin (empa) before planned dose by day.
This endpoint in steady state is identical to Cmin,ss.</description>
          <population>Pharmacokinetic (PK) analysis set included all evaluable patients documented to have taken at least one dose of investigational treatment and who provided at least one observation for at least one PK endpoint.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.64" spread="1.24"/>
                    <measurement group_id="O2" value="70.54" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.70" spread="1.23"/>
                    <measurement group_id="O2" value="80.27" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.24" spread="1.24"/>
                    <measurement group_id="O2" value="78.96" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.10" spread="1.22"/>
                    <measurement group_id="O2" value="72.74" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.21" spread="1.23"/>
                    <measurement group_id="O2" value="76.02" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Protocol-Specified Significant Adverse Events, Hypoglycaemic Events, Vital Signs, Blood Chemistry, Rescue Therapy, Body Weight and Waist Circumference</title>
        <description>Clinically relevant abnormalities for protocol-specified significant adverse events, hypoglycaemic events, vital signs, blood chemistry, use of rescue therapy, change in body weight and change in waist circumference.
Results shown are for hypoglycaemic events, as this was the only event that occurred for this endpoint.</description>
        <time_frame>Drug administration until end of trial, up to 21 days</time_frame>
        <population>Treated set (TS) includes all patients who were documented to have taken at least one dose of investigational treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo tablets, one matching the empa 10mg tablet and one matching the empa 25mg tablet, taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period).</description>
          </group>
          <group group_id="O2">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period). Along with this a placebo tablet matching the 25mg empa tablet was taken at each drug administration.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period). Along with this a placebo tablet matching the 10mg empa tablet was taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Protocol-Specified Significant Adverse Events, Hypoglycaemic Events, Vital Signs, Blood Chemistry, Rescue Therapy, Body Weight and Waist Circumference</title>
          <description>Clinically relevant abnormalities for protocol-specified significant adverse events, hypoglycaemic events, vital signs, blood chemistry, use of rescue therapy, change in body weight and change in waist circumference.
Results shown are for hypoglycaemic events, as this was the only event that occurred for this endpoint.</description>
          <population>Treated set (TS) includes all patients who were documented to have taken at least one dose of investigational treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Glucose Excretion (UGE) Change From Baseline</title>
        <description>Change from day -1 in urinary glucose excretion in a 24 hour collection period per time point.</description>
        <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
        <population>Pharmacodynamic analysis (PD) set included all patients documented to have taken at least one dose of investigational treatment, who received at least one dose of empagliflozin or placebo and who provided at least one baseline and post-treatment observation for at least one PD endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo tablets, one matching the empa 10mg tablet and one matching the empa 25mg tablet, taken orally for 7 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Glucose Excretion (UGE) Change From Baseline</title>
          <description>Change from day -1 in urinary glucose excretion in a 24 hour collection period per time point.</description>
          <population>Pharmacodynamic analysis (PD) set included all patients documented to have taken at least one dose of investigational treatment, who received at least one dose of empagliflozin or placebo and who provided at least one baseline and post-treatment observation for at least one PD endpoint.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-988.38" spread="2791.68"/>
                    <measurement group_id="O2" value="87680.85" spread="22924.91"/>
                    <measurement group_id="O3" value="82791.86" spread="18752.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4106.10" spread="6428.12"/>
                    <measurement group_id="O2" value="95765.72" spread="24133.47"/>
                    <measurement group_id="O3" value="82633.88" spread="34757.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline</title>
        <description>Fasting Plasma Glucose (FPG) change from baseline between day 1 and day 9.</description>
        <time_frame>Sampling intervals were 0-2 hours (h), 2-4h, 4-8h, 8-12h and 12-24h after drug administration</time_frame>
        <population>Pharmacodynamic analysis (PD) set included all patients documented to have taken at least one dose of investigational treatment, who received at least one dose of empagliflozin or placebo and who provided at least one baseline and post-treatment observation for at least one PD endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two placebo tablets, one matching the empa 10mg tablet and one matching the empa 25mg tablet, taken orally for 7 consecutive days.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10 mg</title>
            <description>10 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 25mg empa tablet taken at each drug administration.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25 mg</title>
            <description>25 mg empagliflozin (empa) taken orally once daily for 7 consecutive days, plus a placebo tablet matching the 10mg empa tablet taken at each drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline</title>
          <description>Fasting Plasma Glucose (FPG) change from baseline between day 1 and day 9.</description>
          <population>Pharmacodynamic analysis (PD) set included all patients documented to have taken at least one dose of investigational treatment, who received at least one dose of empagliflozin or placebo and who provided at least one baseline and post-treatment observation for at least one PD endpoint.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.67" spread="7.45"/>
                    <measurement group_id="O2" value="-25.56" spread="20.74"/>
                    <measurement group_id="O3" value="-31.44" spread="26.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Drug administration until end of trial, up to 21 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Two placebo tablets, one matching the empa 10mg tablet and one matching the empa 25mg tablet, taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period).</description>
        </group>
        <group group_id="E2">
          <title>Empa 10 mg</title>
          <description>10 mg empagliflozin (empa) taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period). Along with this a placebo tablet matching the 25mg empa tablet was taken at each drug administration.</description>
        </group>
        <group group_id="E3">
          <title>Empa 25 mg</title>
          <description>25 mg empagliflozin (empa) taken orally either as a single dose (single dose period) or for 7 consecutive days (multiple dose period). Along with this a placebo tablet matching the 10mg empa tablet was taken at each drug administration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>White blood cell disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Eosinophil count abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutrophil count abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

